about
Tuberculosis and HIV co-infectionInhibition of HIV-1 disease progression by contemporaneous HIV-2 infectionInternational network for comparison of HIV neutralization assays: the NeutNet report IIThe nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infectionIncreased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition.Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus MacaquesPlasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count.Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry.Elevated levels of invariant natural killer T-cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 infections.Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolateSensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates.CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection.The evolution of HIV-1 interactions with coreceptors and mannose C-type lectin receptors.Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain.Ugandan HIV-1 V3 loop sequences closely related to the U.S./European consensus.Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load.Prognostic value of a CCR5 defective allele in pediatric HIV-1 infection.Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.Dendritic Cell Response to HIV-1 Is Controlled by Differentiation Programs in the Cells and Strain-Specific Properties of the Virus.Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.Cocirculation of several similar but unique HIV-1 recombinant forms in Guinea-Bissau revealed by near full-length genomic sequencing.Role of immunity in maternal-infant HIV-1 transmission.Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness.Faster progression to AIDS and AIDS-related death among seroincident individuals infected with recombinant HIV-1 A3/CRF02_AG compared with sub-subtype A3.R5 human immunodeficiency virus type 1 with efficient DC-SIGN use is not selected for early after birth in vertically infected children.Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency.Mycobacteria-infected bystander macrophages trigger maturation of dendritic cells and enhance their ability to mediate HIV transinfection.Patterns of immunoglobulin G subclass reactivity to HIV-1 envelope peptides in children born to HIV-1-infected mothers.Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates.
P50
Q21131403-E16C3642-484B-4FED-A5D2-F7A6625FB035Q28271332-D0655A05-C2D5-41A6-BBEF-892CD44E79EBQ28730045-4F20059C-47E6-456E-A75D-9782D5777C0EQ32050235-3675491C-B087-405A-A11D-0C11E35A9F23Q33686847-2911414C-B8E3-44AB-8030-5F126A753AE6Q33916550-8F4A192C-BD99-4018-9F02-1B9E591ED553Q33941033-CE9BECA8-7204-4F46-9DF0-5587E08E3916Q33955745-DA012F0E-8ABC-453D-A3A5-E199B2E3E8F9Q34667609-A4AF636A-D820-4FC5-8478-3F7A5FCB7619Q34984724-48AE618C-4FD8-47EF-B8C3-6E90B6E78935Q35077438-D455E20C-716E-4E81-B1F3-C4A7FF8F5D73Q35665921-9B88D783-45AF-4D51-A92B-56D7E021DE7CQ35826692-406BDF90-888C-4992-AB5F-9CB7BA4A8842Q35858793-144E9292-476D-4FA7-BC65-1139713A0CA3Q36506821-D07990C0-66F1-40B7-851F-3EB6BEFA7F93Q36580487-4784CA58-E8BC-4531-91DF-FA52840839E3Q36634790-508A338B-9422-41D1-B8D1-CF1B9E39A382Q36844406-423A551F-B438-42C1-94F2-9316D45E9343Q37048079-9D42FF15-6509-49A8-82C8-13633E7DBD00Q37060319-9611A213-DFE2-44EC-BBA5-A83F3D42B2E0Q37094738-62349773-F71E-4B1F-9AD7-6E0C15C6B039Q37312729-2E87A2E4-7118-437A-B0FB-33F33ED6FB6BQ38321422-B391E02B-9D31-47FF-9F4A-E957EB782C0EQ38889541-E2571255-CC52-4FF0-823A-3697C03329DEQ38890214-D4C9C918-292C-4A6D-A9F4-E7E7E0D46AC1Q39121838-40266D19-76B3-4216-A434-15C9223EC15DQ39407231-0CF408AF-6AD8-49C8-8150-51B0066AA786Q40213577-A19FAEE5-97C7-4FBF-B736-75E7B3457815Q40271149-8FC8E8E2-799D-4296-AB60-30D1F210319DQ40349284-1737FE48-91D8-4256-9446-2031528F8749Q40844351-8B8EC2A3-190A-455D-AAA3-909C44CEEEF1Q41548417-1A083788-4107-4134-A87D-F22B096E20B5Q41899294-D459DEB5-C2B3-4787-A860-6C10C6A69816Q42277493-05E848F0-BE01-4524-9EFF-575FFF6E4791Q42283314-05973FBD-2431-43C5-BC27-7BD06160E18FQ42600049-ED9A793E-29C0-49A1-8BBE-D0E89CD1650BQ43776748-9273AFE0-E758-49E8-B010-6979A54E9FBEQ44248125-E6060B96-721B-4848-A1C7-338DF298F768Q45423694-578075F0-30FD-4F89-9F13-1B1604409FBAQ45733791-02DEDB17-06EE-4662-A97A-19A64D7C757F
P50
description
Zweeds onderzoekster
@nl
researcher ORCID ID = 0000-0001-6536-8146
@en
name
Marianne Jansson
@ast
Marianne Jansson
@en
Marianne Jansson
@es
Marianne Jansson
@nl
Marianne Jansson
@sl
type
label
Marianne Jansson
@ast
Marianne Jansson
@en
Marianne Jansson
@es
Marianne Jansson
@nl
Marianne Jansson
@sl
prefLabel
Marianne Jansson
@ast
Marianne Jansson
@en
Marianne Jansson
@es
Marianne Jansson
@nl
Marianne Jansson
@sl
P106
P21
P27
P31
P496
0000-0001-6536-8146